Skip to main content

06.06.19 1:00 PM ET | EGPA Webinar

Learning Objectives
Upon completion of the educational activity, participants should be able to:

  • Review the clinical presentation and signs and symptoms of EGPA
  • Describe the ANCA-associated vasculitides
  • Describe the diagnostic evaluation of EGPA
  • Identify treatment options for initial therapy and for recalcitrant disease

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Commercial Support
This educational activity is supported by an educational grant from GlaxoSmithKline.

Criteria for Success
Statements of credit will be awarded based on the participant's attendance, participation in the pre/post-test and submission of the activity evaluation form. A passing score of 70% on the quiz is required to receive credit. A certificate will be available in your transcripts upon successful completion of the quiz and evaluation. If you have questions about this CME activity, please contact AKH Inc. at There is no fee for this activity.

Praveen Akuthota, MD
Associate Professor of Medicine
University of California San Diego
San Diego, CA

Dr. Akuthota received his medical degree from Case Western Reserve University. He trained in internal medicine at Beth Israel Deaconess Medical Center and Harvard Medical School, where he served as a chief medical resident. He then trained in pulmonary and critical care medicine at Harvard, including post-doctoral research training in eosinophil immunobiology. He was a faculty member at Beth Israel Deaconess and Harvard Medical School prior to joining the faculty at University of California San Diego in 2015. Dr. Akuthota maintains an active clinical practice at with a focus on asthma and eosinophilic pulmonary disease, with expertise in biologic therapies. He is also an attending physician in the medical ICU at the UC San Diego Hillcrest Medical Center. Dr. Akuthota’s research efforts range from basic scientific investigations of human eosinophil biology and eosinophilic inflammation to clinical and translational efforts in asthma and eosinophilic pulmonary disease. He is the corresponding Principal Investigator for the UCSD Clinical Center in the National Heart, Lung, and Blood Institute’s PrecISE Network that will be studying precision interventions in severe asthma. He is a co-investigator on a study published in the New England Journal of Medicine showing the efficacy of anti-IL-5 therapy in the treatment of the eosinophilic disease EGPA (Churg Strauss syndrome). His research group is involved in other multicenter studies in eosinophilic disease and asthma. He is a Clinical Affiliate at the La Jolla Institute for Allergy and Immunology, working with them in developing joint efforts in asthma research ( Basic science investigations from Dr. Akuthota focus on ex vivo studies of human eosinophils and include published work studying eosinophil trafficking and work studying microparticle release by eosinophils. He has written several reviews and chapters discussing eosinophil immunobiology and clinical considerations in eosinophilic diseases. Dr. Akuthota is an At-Large Member of the Board of Directors of the International Eosinophil Society (

Dr Akuthota has disclosed the following relevant financial relationships:
Consultant: AstraZeneca, GlaxoSmithKline
Contracted Research: AstraZeneca, GlaxoSmithKline

Philip Seo, MD, MHS
Director, The Johns Hopkins Vasculitis Center
Johns Hopkins University
Director, Johns Hopkins Rheumatology Fellowship
Johns Hopkins University
Baltimore, MD

Dr. Philip Seo is an Associate Professor in the Division of Rheumatology. A graduate of Harvard College and the College of Physicians and Surgeons at Columbia University, Dr. Seo completed his Internal Medicine training as a member of the Osler Medical Service at the Johns Hopkins Hospital. Since then, he has worked at Johns Hopkins in several capacities, including as a hospitalist at Johns Hopkins Bayview Medical Center, and as an Assistant Chief of Service of the Department of Medicine at the Johns Hopkins Hospital, before joining the Division of Rheumatology.
Dr. Seo is the Director of the Johns Hopkins Vasculitis Center and Director of the Johns Hopkins Rheumatology Fellowship Program. His clinical interests lie in the assessment and treatment of patients with systemic vasculitis, in particular, the ANCA-associated vasculitides, which include granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis.

Dr Seo has disclosed no financial relationships.

Michael E. Wechsler, MD
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
National Jewish Health
Denver, CO

Michael E. Wechsler is Director of the National Jewish Health (NJH)/Cohen Family Asthma Institute and Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at NJH in Denver. Professor Wechsler’s research focuses on clinical and translational asthma with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome, CSS). He has led studies focusing on novel biologic agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepalumab. He has published more than 175 peer-reviewed manuscripts relating to asthma, CSS and eosinophilic lung diseases. He is a member of the Steering Committee and site Principal Investigator of the NIH-sponsored Asthma Clinical Research Network (ACRN, now called AsthmaNet), a multicentre asthma clinical trials consortium, and of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network. A member of the American Society of Clinical Investigation, he has participated in many different task forces related to the study of eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society and the International Eosinophil Society. He has served as Associate Editor of the journal Allergy and on the editorial board of the European Journal of Clinical Investigation.
Dr. Wechsler received AB and MMSc degrees from Harvard University in Boston and an MD degree from McGill University in Montreal. He completed medical training at Beth Israel Hospital in Boston, and as part of the Harvard Combined Pulmonary and Critical Care Fellowship Training Program.

Dr. Wechsler has disclosed the following relevant financial relationships:
Consultant: AstraZeneca, Boehringer Ingelheim, Glaxosmithkline, Novartis, Regneeron, Sanofi, Teva
Contracted Research: AstraZeneca, Novartis, Sanofi, Teva

Lynne Kolton Schneider, PhD, Medical Writer/Interviewer: has discloses no financial relationships.
Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner: has discloses no financial relationships.
Patricia Brignoni, AKH Director of Operations: has discloses no financial relationships.
Steve Eckert, AKH President & CEO, Planner: has discloses no financial relationships.

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

Copyright 2018 AKH Inc. No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publisher.